Pharmaceutical

In a significant move that marks the largest biotech acquisition since 2023, Johnson & Johnson has announced its agreement to purchase neuroscience drugmaker Intra-Cellular Therapies for £14.6 billion. The New Jersey-based…

In a devastating blow to investor confidence, Moderna's shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant. The Boston-headquartered company revised its…

Liverpool's burgeoning life sciences sector is positioning itself as one of Europe's premier biotech clusters, with projections indicating up to £800 million in investment over the next decade. The region's ambitious growth plans include…

The struggling consumer healthcare company Alliance Pharma appears poised to exit London's junior stock exchange following a £350 million takeover bid from activist investor Dbay Advisors. The Isle of Man-based investment firm, which holds…

A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as Europe's largest…

A landmark research initiative analysing blood proteins could catalyse significant advancements in disease treatment and prevention, presenting substantial opportunities for healthcare sector investors. The extensive UK-based study, backed…

British pharmaceutical giant GSK is in advanced negotiations to acquire IDRx, a Massachusetts-based biotechnology company, in a deal valued at approximately $1 billion. The announcement is expected to coincide with the upcoming JP Morgan…

Share prices of leading vaccine developers experienced significant gains on Tuesday following the announcement of America's first human death from the H5 strain of bird flu. The market response saw Moderna's stock surge by 11.6 per cent,…

Novo Nordisk, the Danish pharmaceutical powerhouse, has invested hundreds of thousands of pounds in sponsorship deals with major UK pharmacy chains, including Boots and Lloyds, to enhance sales of its weight-loss medications. The…

The UK pharmacy sector witnessed a significant wave of consolidation as nearly one in ten pharmacies were acquired through mergers and acquisitions in the 12 months to June 2024, amid mounting profit pressures and rising operational costs.…

British pharmaceutical giant AstraZeneca has distributed approximately £45 million to Russian healthcare professionals and organisations since the outbreak of the Ukraine war, despite mounting UK military support for Kyiv. The…

The aggressive marketing of weight-loss injections to British consumers has sparked significant concern amongst healthcare experts, who are witnessing what they describe as a "wild west" approach to pharmaceutical promotion. Online…

A groundbreaking personalised cancer treatment is emerging from an unexpected location: Stevenage High Street. UK biotech firm Autolus has received FDA approval to manufacture and distribute its innovative Car-T cell therapy, Aucatzyl,…

In a significant strategic pivot, artificial intelligence drug discovery company BenevolentAI is contemplating a return to the London markets by 2026, following its planned delisting from Euronext Amsterdam. The company's founder, Ken…

Danish pharmaceutical giant Novo Nordisk witnessed a staggering $100 billion erosion in market value following disappointing results from its latest obesity drug trial. The company's shares experienced their most significant single-day…

The United Kingdom's weight-loss medication market has witnessed an unprecedented surge, with more than 500,000 individuals now utilising revolutionary anti-obesity drugs Mounjaro and Wegovy. This dramatic increase has occurred within just…

In a significant development for the UK healthcare sector, the NHS has announced the introduction of a groundbreaking once-daily tablet for advanced breast cancer treatment. This strategic move is projected to benefit over 1,000 women and…

In a significant move strengthening its technological capabilities, AstraZeneca has appointed Arm Holdings Chief Executive Rene Haas to its board as a non-executive director, effective from next month. The appointment comes as Britain's…